Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults - 16/02/16
, Thomas Bieber, MD b, Laurent Eckert, PhD c, Richard Wu, PhD d, Marius Ardeleanu, MD d, Neil M.H. Graham, MD d, Gianluca Pirozzi, MD, PhD c, Vera Mastey, MSc dAbstract |
Background |
The adult burden of atopic dermatitis (AD) is poorly characterized.
Objective |
We sought to characterize AD burden in adults with moderate to severe disease from the patient's perspective.
Methods |
Patient-reported outcomes collected at screening in a phase 2b clinical trial of dupilumab included pruritus numeric rating scale, 5-Dimension Pruritus Scale, subjective components of SCORing AD, Patient-Oriented Eczema Measure, Hospital Anxiety and Depression Scale, Dermatology Life Quality Index, and 5-Dimension EuroQol.
Results |
Most of the 380 patients had been living with AD for nearly all their lives, whereas approximately 40% were given a diagnosis as adults; 40.3% had asthma and 60.5% had other allergic conditions. Despite 48.2% of patients using systemic therapies in the past year, patients reported problems with itch frequency (85% of patients), duration (41.5% reported itching ≥18 h/d), and severity (6.5 of 10 on numeric rating scale); 55% reported AD-related sleep disturbances 5 d/wk or more. Hospital Anxiety and Depression Scale scores suggesting clinically relevant anxiety or depression were reported by 21.8% of patients. Quality of life was impaired on Dermatology Life Quality Index and 5-dimension EuroQol.
Limitations |
This study had limited generalizability; conclusions may not reflect those with mild AD or not participating in a clinical trial.
Conclusions |
Adults with moderate to severe AD report multidimensional burden including disease activity, patient-reported symptoms, comorbidities, and quality-of-life impact.
Le texte complet de cet article est disponible en PDF.Key words : adults, atopic dermatitis, burden of illness, patient-reported outcomes, pruritus, quality of life
Abbreviations used : AD, DLQI, EQ-5D, HADS, HRQoL, IL, POEM, SCORAD, VAS
Plan
| Supported by Sanofi and Regeneron Pharmaceuticals, Inc. Editorial support for the preparation of this manuscript was provided by E. Jay Bienen, PhD, funded by Regeneron Pharmaceuticals, Inc. |
|
| Disclosure: Dr Simpson or his institution received grants/research support from Amgen, Asubio Pharmaceuticals, Celgene, Chugai, Galderma, Genentech, MedImmune, Regeneron Pharmaceuticals, Inc, and Tioga; is a consultant for Galderma, Genentech, MedImmune, and Regeneron Pharmaceuticals, Inc; served on advisory boards for Celgene, Pfizer, and Valeant; and served as a speaker for Anacor and Regeneron Pharmaceuticals, Inc. Dr Bieber is an investigator and consultant for Regeneron Pharmaceuticals, Inc; received honoraria, advisory board, or consulting fees provided by Novartis, Astellas, and Atopix; and received grant support from Astellas, Atopix, and MSD. Drs Eckert and Pirozzi are employees of Sanofi and may hold stock and/or stock options in the company. Drs Wu, Ardeleanu, and Graham and Ms Mastey are employees and shareholders of Regeneron Pharmaceuticals, Inc. |
Vol 74 - N° 3
P. 491-498 - mars 2016 Retour au numéro
Article précédent
- Impact of store-and-forward (SAF) teledermatology on outpatient dermatologic care: A prospective study in an underserved urban primary care setting
- Caroline A. Nelson, Junko Takeshita, Karolyn A. Wanat, Kent D.W. Bream, John H. Holmes, Helen C. Koenig, Rudolf R. Roth, Anitha Vuppalapati, William D. James, Carrie L. Kovarik
- Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial
- Hesham Zaher, Hoda Rasheed, Mohamed M. El-Komy, Rehab A. Hegazy, Heba I. Gawdat, Dalia M. Abdel Halim, Rania M. Abdel Hay, Ranya A. Hegazy, Abeer M. Mohy
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?